Publications | BMT CTN

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

Found 14 results

Filters: Author is Hari, Parameswaran [Clear All Filters]

2022

A. Dispenzieri, Krishnan, A., Arendt, B., Blackwell, B., Wallace, P. K., Dasari, S., Vogl, D. T., Efebera, Y., Fei, M., Geller, N., Giralt, S., Hahn, T., Howard, A., Kohlhagen, M., Landau, H., Hari, P., Pasquini, M. C., Qazilbash, M. H., McCarthy, P., Shah, N., Vesole, D. H., Stadtmauer, E., and Murray, D., “Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).”, Blood Cancer J, vol. 12, no. 2, p. 27, 2022.

Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., “A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.”, Transplant Cell Ther, 2022.

A. D'Souza, Brazauskas, R., Stadtmauer, E. A., Pasquini, M. C., Hari, P., Bashey, A., Callander, N., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Landau, H., Brunstein, C., McCarthy, P., Qazilbash, M. H., Giralt, S., Krishnan, A., and Flynn, K. E., “Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.”, Am J Hematol, 2022.

2021

H. E. Heslop, Stadtmauer, E. A., Levine, J. E., Ballen, K. K., Bin Chen, Y. -, DeZern, A. E., Eapen, M., Hamadani, M., Hamilton, B. K., Hari, P., Jones, R. J., Logan, B. R., Kean, L. S., Leifer, E. S., Locke, F. L., Maziarz, R. T., Nemecek, E. R., Pasquini, M., Phelan, R., Riches, M. L., Shaw, B. E., Walters, M. C., Foley, A., Devine, S. M., and Horowitz, M. M., “Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.

L. J. Costa, Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, N. S., Chng, W. Joo, Hungria, V., Maiolino, A., Stadtmauer, E., Giralt, S., Pasquini, M., Jakubowiak, A. J., Morgan, G. J., Krishnan, A., Jackson, G. H., Mohty, M., Mateos, M. Victoria, Dimopoulos, M. A., Facon, T., Spencer, A., San Miguel, J., Hari, P., Usmani, S. Z., Manier, S., McCarthy, P., Kumar, S., Gay, F., and Paiva, B., “International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.”, Leukemia, vol. 35, no. 1, pp. 18-30, 2021.

2020

L. J. Costa, Iacobelli, S., Pasquini, M. C., Modi, R., Giaccone, L., Blade, J., Schonland, S., Evangelista, A., Perez-Simon, J. A., Hari, P., Brown, E. E., Giralt, S. A., Patriarca, F., Stadtmauer, E. A., Rosinol, L., Krishnan, A. Y., Gahrton, G., and Bruno, B., “Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.”, Bone Marrow Transplant, vol. 55, no. 9, pp. 1810-1816, 2020.

S. A. Holstein, Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L., and McCarthy, P. L., “Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.”, Biol Blood Marrow Transplant, vol. 26, no. 1, pp. e7-e15, 2020.

S. Giralt, Costa, L. J., Maloney, D., Krishnan, A., Fei, M., Antin, J. H., Brunstein, C., Geller, N., Goodman, S., Hari, P., Logan, B., Lowsky, R., Qazilbash, M. H., Sahebi, F., Somlo, G., Rowley, S., Vogl, D. T., Vesole, D. H., Pasquini, M., and Stadtmauer, E., “Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.”, Biol Blood Marrow Transplant, vol. 26, no. 4, pp. 798-804, 2020.

2019

E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.”, J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.

J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., “Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with ”, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.

2017

A. D'Souza, Pasquini, M., Logan, B., Giralt, S., Krishnan, A., Antin, J., Howard, A., Goodman, S., Qazilbash, M., Knust, K., Sahebi, F., Weisdorf, D., Vesole, D., Stadtmauer, E., Maloney, D., and Hari, P., “Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.”, Br J Haematol, vol. 178, no. 5, pp. 816-819, 2017.

S. A. Holstein, Jung, S. - H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., van Besien, K., Gentile, T. G., Isola, L., Maziarz, R. T., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Rodriguez, C., McClune, B., Schlossman, R. L., Smith, S. E., Hars, V., Owzar, K., Jiang, C., Boyd, M., Schultz, C., Wilson, M., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Linker, C., Anderson, K. C., and McCarthy, P. L., “Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.”, Lancet Haematol, vol. 4, no. 9, pp. e431-e442, 2017.

2012

P. L. McCarthy, Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. Scott, van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., and Linker, C., “Lenalidomide after stem-cell transplantation for multiple myeloma.”, N Engl J Med, vol. 366, no. 19, pp. 1770-81, 2012.